The 42nd LifeScienceNet Düsseldorf meeting held on March 12, 2019, provided an excellent networking platform for several innovative companies. Sören Liebig, CEO at MukoCell GmbH presented their innovative and gentle method for the surgical repair of urethral strictures. Instead of removing large segments of oral mucosa the replacement tissue for the urether is cultured with the help of an autologous cell transplant (Mukocell®) expanded from minute amounts of mucosal tissue.
Mukocell® is a registered ATMP (Advanced Therapy Medicinal Product) and has already been used in about 200 patients. A Phase 2 clinical study with 99 treatments showed the efficacy and safety of the product and no adverse events were reported. The next step is a Phase 3 trial with 200 patients in three different countries that will start mid 2019. The results of the study will be used to apply for reimbursement approval in Germany and market authorization in the US. MLM has been selected by MukoCell® as the central laboratory for this phase 3 study and is very proud to support MukoCell® in the improvement of the quality of patient’s life.